Pzena Investment Management Regeneron Pharmaceuticals Inc transactions over time
REGN
Regeneron Pharmaceuticals Inc historical holders
total: 9
Transactions details
- Total transactions:
- 9
- New positions:
- 2
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 4
- Held since:
- 2026 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q3
Richard Pzena has been an institutional investor in Regeneron Pharmaceuticals Inc (REGN) since 2021 Q1. According to 2026 Q3 report, Richard Pzena holds 409 shares with a market value of roughly $310.13K representing 0.00% of their equity portfolio. The fund/company first acquired REGN in 2021 Q1, initially purchasing 1,255 shares. Richard Pzena later completely sold out the position and reinvested in REGN again in 2026 Q3. Since the initial investment, Pzena Investment Management has made 8 more transactions in this position.
Does Richard Pzena still hold REGN?
Yes, Richard Pzena continues to hold Regeneron Pharmaceuticals Inc (REGN). According to their 2026 Q3 report, they maintain a position of 409 shares valued at approximately $310.13K, representing 0.00% of their equity portfolio.
When did Richard Pzena first invest in REGN?
Richard Pzena first invested in Regeneron Pharmaceuticals Inc (REGN) in 2021 Q1 at the reported quarter-end price of $473.31 per share, acquiring 1,255 shares in their initial purchase.
What is Richard Pzena's average cost basis for REGN?
Based on historical transaction data, Richard Pzena's estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) is approximately $758.27 per share. This represents their average reported price* across all buy transactions.
Has Richard Pzena reinvested in REGN after selling?
Yes, Richard Pzena has shown renewed interest in Regeneron Pharmaceuticals Inc (REGN). After completely selling their position, they reinitiated an investment in 2026 Q3, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $758.27
REGN transactions history by Pzena Investment Management
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
0.00%
|
409
|
$758.27
|
$310,132
|
new
|
+0%
|
|
2022 Q4
|
0.00%
|
0
|
$688.92
|
|
-100% (-794)
|
-0%
|
|
2022 Q3
|
0.00%
|
794
|
$688.92
|
$547,000
|
-29.04% (-325)
|
-0%
|
|
2022 Q2
|
0.00%
|
1,119
|
$590.71
|
$661,000
|
+21.10% (+195)
|
+0%
|
|
2022 Q1
|
0.00%
|
924
|
$698.05
|
$645,000
|
+2.21% (+20)
|
+0%
|
|
2021 Q4
|
0.00%
|
904
|
$631.64
|
$571,000
|
-7.47% (-73)
|
-0%
|
|
2021 Q3
|
0.00%
|
977
|
$604.91
|
$591,000
|
-12.30% (-137)
|
-0%
|
|
2021 Q2
|
0.00%
|
1,114
|
$558.35
|
$622,000
|
-11.24% (-141)
|
-0%
|
|
2021 Q1
|
0.00%
|
1,255
|
$473.31
|
$594,000
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.